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ABSTRACT
ARTERIAL AND VENOUS IMPACTS OF
TRANSDERMALLY ADMINISTERED VASODILATORS
ON THE LOCAL MICROVASCULATURE
George Guo, B.A., Katherine Chuang, B.S., Nitin Sukumar, M.S., Feng Dai, Ph.D.,
David G. Silverman, M.D., Kirk Shelley, M.D/Ph.D., D.P.M., Aymen Alian, M.D. Yale
University School of Medicine, Department of Anesthesiology, New Haven, CT.
Microcirculatory function is an important component of cardiovascular pharmacology
as related to cardiovascular dysfunction. We used photoplethysmography (PPG) to
compare the microcirculatory effects of transdermal patches of rivastigmine (Exelon,
Novartis), nicotine, nitroglycerin (NTG) and topically applied EMLA (eutectic mixture
of lidocaine/prilocaine). We anticipate that this initial pilot comparison of single doses
of each medication will catalyze future multi-dose comparisons of the various
vasodilatory features of these and other drugs.
Methods: With IRB approval, 10 healthy volunteers were monitored with PPG at the
time each transdermal patch was applied and every 8 minutes afterwards for a total of
40 minutes. 1x1 cm portions of patches of rivastigmine, nicotine, and NTG were placed
and monitored on different sites of the forehead. Another site was isolated and
pretreated 6 hours earlier with EMLA, since this drug requires many hours to induce
vasodilation.1 All voltage changes were changed to ACmults, i.e., in multiples of the
change in voltage associated with delivery of the stroke volume to the given site under
resting conditions2. A linear mixed model was used to compare patch effects on
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maximum change in AC, DC, and ΔAC/ΔDC. This model accounts for the variance that
can be attributed to an individual’s multiple measurements within an unstructured
covariance matrix. A p-value <0.05 was given to be statistically significant. Data were
expressed as mean within a 95% confidence interval.
Results: The max ∆AC change for each drug were significantly different from that of
its control while only the max ∆DC of NTG was significantly greater than that of its
control. Changes in the ΔAC/ΔDC ratio were found to be inconsistent. Rivastigmine
and control had significantly lower ΔAC/ΔDC values at 8 minutes compared to that of
EMLA; the differences were not significant at following time points.
Discussion: These results may provide some insight into the cardiovascular effects of
the study agents used. NTG, a direct NO donor, caused significant increases in AC
(arteriolar) and DC (venous) values. Acting at the pre/post ganglionic junction of local
parasympathetic pathways to the region of the precapillary sphincter, nicotine caused a
significant increase in AC, whereas the change in DC was not found to be significant.
Rivastigmine, which inhibits the metabolic degradation of acetylcholine, caused a
selective increase in AC. The local anesthetic (EMLA) caused a significant increase in
AC. Rivastigmine caused significantly lower ΔAC/ΔDC ratio at 8 minutes when
compared to EMLA (which had been on for 6 hours previously). At >16 minutes, the
ΔAC/ΔDC values of rivastigmine and EMLA did not differ significantly, findings that
may reflect the time needed for acetylcholine to to increase over time via the inhibition
of its breakdown as opposed to an immediate introduction of additional agonist via the
nicotine or NTG patch. Future studies using different and/or additional drug

	
  
combinations may help give further insight into the convoluted physiology of the
microvasculature.

*The above abstract was presented at the American Society of Anesthesiologists 2016
annual meeting.
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INTRODUCTION
Photoplethysmography (PPG) is a simple and low-cost optical technique that is
used non-invasively at the surface of the skin to detect blood volume changes in
microcirculation [1]. Photoplethysmography was first rendered in 1938 by Hertzman of
the United States and Matthes and Hauss of Germany and has since been extensively
studied and used in a wide range of commercially available medical devices for
measuring oxygen saturation, blood pressure and cardiac output, assessing autonomic
function and detecting peripheral vascular disease [2, 3].
Since its conception, the PPG has contributed to improvements in clinical
practice but has also continued to mystify physicians and researchers. Though the
origins of the PPG signal are not fully understood, it is generally accepted that they can
provide valuable information about the cardiovascular system [4]. In the 1970s, a major
advancement in the clinical use of a PPG-based technology came when its utility as a
non-invasive method for monitoring patients’ arterial oxygen saturation was realized
[5]. Since then, the PPG has been used in various other clinical applications and is now
in several commercially available medical devices - pulse oximeters, vascular
diagnostics, and digital beat-to-beat blood pressure measurement systems. This success
has been possible despite the characteristics of the PPG waveform from being
thoroughly studied and understood; more research needs to be done to uncover the
myriad of physiologically relevant information contained in the PPG.
This study will build on previous work done in our laboratory that converts
changes in PPG voltage to changes in blood flow in the local environment secondary to
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locally targeted vasodilators. We will use PPG monitoring to see if any differences can
be seen in arterial and venous blood flow between different vasodilatory drugs.
PHOTOPLETHYSMOGRAPHY
PPG uses a light source to illuminate tissue (usually the skin) and a
photodetector that measures small variations in light intensity associated with changes
in perfusion in the local microvasculature. It is often used at the red or near infrared
wavelength to facilitate measurement of blood flow. The photodetector converts light
energy into an electrical current, which is connected to low noise electronic circuitry
that includes a transimpedance amplifier and filtering circuitry [3].
There are two configurations of photoplethysmography that can be utilized in
practice. The most common modality is “transmission mode” in which tissue is placed
between a light-emitting diode and a photodetector, e.g. across a fingertip or earlobe
(see Figure 1A). A pulse of blood increases both the optical density and path length
through the illuminated tissue, a process that decreases the light intensity at the
photodetector. In “reflectance mode,” the photodetector is placed alongside the lightemitting diode (see Figure 1B) and records the light that returns after being reflected by
non-hemolyzed red blood cells [6].

A.
B.
Figure 1. Configurations of PPG in transmission mode (A) and reflection mode (B).
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The quantitative relation between blood perfusion through an irregular network

of vessels, and the fraction of photons that pass through the tissue or is reflected, is
complicated. The Beer-Lambert law gives us a way to understand the PPG waveform in
more simplistic terms; in other words, assuming a uniform and diffuse layer of blood
perpendicular to a beam of light and taking into consideration only light absorption (not
scatter, refraction, reflection), the Beer-Lambert law states that light intensity decays as
a function of distance exponentially [6].
There are two components to parcel out with regard to the PPG waveform. The
baseline level of the photoplethysmogram is referred to as the direct current (DC) and is
a relative index of skin vascularity that is affected by perturbations in thermoregulation,
respiration, metabolic state, drugs, central and local regulatory mechanisms [6]. This
baseline is not steady but contains low-frequency oscillations due to changes in
recruited capillary densities and venous volume fluctuations. These oscillations have
been found even distal to an arterial tourniquet, which may represent sympathetically
mediated shifting of blood between different compartments of the peripheral
microcirculation [7]. The pulsatile waveform attributed to changes in blood volume
generated by individual heart beats is referred to the alternative current (AC) and is a
manifestation of cardiac stroke volume typically seen around 1 Hz (See Figure 2). This
is, as stated, superimposed on top of the slowly varying DC baseline which relates more
to tissue (See Figure 3) including skin, bone, muscle and average blood volume [3].
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Figure 2. The pulsatile (AC) component of the PPG and corresponding
electrocardiogram (ECG)

Figure 3. AC & DC components of the PPG

With regard to most commercial pulse oximeters however, the baseline PPG
waveform usually has been electronically processed to remove baseline vacillations and
reduce signal distortions to yield a photoplethysmogram that appears “cleaner.” There is
no one standard method for removing oscillations in the DC baseline; in fact, many
processing algorithms vary among manufacturers and are often proprietary. Some also
“autoscale” the PPG waveform so that the amplitude of the signal is adjusted to fit
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neatly in the display window. Unfortunately, this processing removes much of the
useful information in the PPG waveform.

ASSESSMENT OF ENDOTHELIAL FUNCTION
The endothelium is the layer of thin, single layer of cells that line the interior
surface of blood vessels to form an interface between the circulating blood and the
vessel wall. These cells line the entire circulatory system from the heart to the capillary.
Endothelial cells are involved in many aspects of vascular functionality, including
vasoconstriction and vasodilatation, blood clotting, angiogenesis, atherosclerosis, and
inflammation [3]. Endothelial dysfunction is considered to be an early event in
atherosclerosis and is associated with major risk factors for cardiovascular disease.
Traditionally, endothelial function is assessed non-invasively by an ultrasound to
measure the brachial artery diameter before and after several minutes of blood flow
occlusion in the arm [8]. The change in arterial diameter gives an indication of flow
mediated endothelium-dependent vasodilatation. Unfortunately, the technique is
operator dependent and requires a high degree of skill, which could limit its usefulness
for routine clinical assessments. PPG has also shown potential for the assessment of
endothelial function but is much less costly than the ultrasound approach. The potential
for PPG assessments to assess vasodilatation has been demonstrated using
hemodynamic responses to nitroglycerin (NTG) therapy [9]. Understanding the
physiology of the microvasculature is a vital part of understanding endothelial
dysfunction, a key component of cardiovascular disease. As nitroglycerin is but one of
many types of vasodilatory drugs, our laboratory aims to use NTG and other drugs
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(rivastigmine, nicotine and an eutectic mix of local anesthetics, i.e. EMLA) to further
refine the PPG as an instrument to better understand what may be occurring at the level
of the microvasculature in response to specific, locally-targeted vasodilatory drugs. This
is especially interesting within the context of testing more than one drug at the same
time and seeing potential additive effects on the local microvasculature.
To date, sildenafil, commonly known as Viagra, is the most commercially
successful drug ever launched. As a potent vasodilator, it is prescribed to increase the
flow of blood to the penis to treat erectile dysfunction. Despite its efficacy or perhaps
because of it, many have reported on its interaction with NTG, a potent vasodilator
commonly prescribed to treat heart disease, to produce potentially lethal hypotension.
Sildenafil, a phosphodiesterase-5 inhibitor (PDE5), blocks the enzyme responsible for
the breakdown of cyclic GMP. NTG is an exogenous organic nitrate that releases nitric
oxide (NO) near vascular smooth muscle cells. Nitric oxide activates soluble guanlyl
cyclase, an enzyme that catalyzes the formation of cGMP from GTP. Thus, by
inhibiting the breakdown of cGMP, the effect of cGMP-dependent protein kinase G
(PKG) is potentiated and induces greater vascular smooth muscle relaxation through the
phosphorylation of myosin light chain kinase (See Figure 4).
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Figure 4. Mechanism whereby sildenafil induces greater vascular smooth muscle
relaxation

Because of the potentially lethal risks involved in testing adverse drug reactions,
effective studies utilizing normal human physiology is difficult. Webb et al found the
coadministration of sildenafil and isosorbide mononitrate resulted in a significantly
greater decrease in both sitting and standing blood pressure than that of the
coadministration of sildenafil and placebo [10]. A double-blind, randomized study led
by Parker et al also found that doses of intravenous NTG (between 5ug/min to
80ug/min) infused after 100mg of sildenafil resulted in a 4 to 6mmHg hypotensive
effect as compared with placebo [11]. However, it would be unwise to extend the results
of this study to interactions of sublingual NTG with sildenafil or other PDE5 inhibitors.
It is therefore important to develop a standard model of study that can be used safely
and consistently in human subjects.
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PURPOSE & HYPOTHESIS
Our laboratory has developed a dual-platform drug model that utilizes
“micropatches” as a way to test and compare the direct effects of a variety of drugs on
the level of the microvasculature in conjunction with a drug taken systemically. Such a
method allows any potential drug interactions to be seen in a localized and controlled
environment that minimizes systemic risk. Furthermore, activation of multiple systemic
responses and reflexes, many of which may modulate the effect at the target site, is
minimized. Thus, the dual-platform drug model is a promising way to evaluate the
effects of NTG and sildenafil taken conjointly, as well as other drugs which may have a
different propensity for inducing vasodilation and hypotension.
Our study is divided into two phases. As NTG, rivastigmine, nicotine and
EMLA induce vasodilation via different physiological mechanisms, the first phase of
our study focuses on comparing their vasodilatory effects on the peripheral
microvasculature without systemic perturbation. In the second phase of our study, we
will use the dual-platform drug model to determine how these effects change with
systemic administration of sildenafil. This thesis will focus its attention primarily on the
first phase as it represents my contribution to a larger study.
In this study, PPG is used as a noninvasive monitor of arterial and venous
microcirculation. We compared the effects of transdermal patches of nicotine,
rivastigmine (dependent upon autonomic pathways and intact endothelium) and NTG
(endothelium-independent) with topically applied EMLA. Because these drugs act
through differing pathways, we hypothesize that specific differences in their local
vasodilatory effects can be captured by information extracted from the PPG waveform.
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MATERIALS & METHODS
With IRB approval, 10 healthy volunteers were enrolled in a double-blind
crossover study conducted over two sessions with a one-week washout period in
between in which subjects were randomized between two days and given either a
placebo pill or a sildenafil pill. Subjects were 10 healthy medical students. All subjects
received verbal and written descriptions of the study protocol with associated risks. An
informed consent approved by the IRB was signed by all volunteers. Though the full
protocol will be described here, this paper will focus its analysis exclusively on sessions
where a placebo pill was used.
During one session, the subject received transdermal translucent patches of
nitroglycerin, rivastigmine, nicotine and EMLA in conjunction with a placebo pill; on
the other day, the subject received the same set of patches in conjunction with sildenafil.
Sildenafil (100mg capsule) and placebo pills were produced and blinded by an external
research pharmacist. Both pills were designed to look and feel identical and were given
to experimenters and subjects in the same fashion in order to preserve double-blinding.
The blinding was broken only after data analysis.
In order to minimize information bias, the sites at which the patches were
administered were randomized between subjects. Because sildenafil no longer interacts
with nitroglycerin 24 hours after sildenafil administration (and may be gone as early as
four hours after sildenafil intake), we anticipated that repeating the study a week later to
be a sufficiently long enough washout period to minimize any carryover effect.
Two hours after sildenafil or placebo administration, we obtained baseline
readings of microvasculature dilation with PPG. 1x1 cm transdermal patches of
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nitroglycerin, rivastigmine, nicotine were then placed and monitored on different
forehead sites randomized between the two sessions, along with a control site that was
also monitored without any drug. A specific template demarcating this area was utilized
that allowed for adequate spacing between all drug sites (See Figure 5). New sites on
the forehead that have not had any drug exposure were then utilized the week after to
minimize potential confounding and carryover effect. In order to compare data points
from the two days (placebo vs sildenafil) for each subject, the same measuring probes
were used to minimize measuring differences that may exist between probes. Of note,
EMLA came prepackaged as a topical cream; an additional 1x1 cm area of the forehead
was pretreated with EMLA for 6 hours and removed before PPG monitoring as this
drug had a longer prodromal phase in comparison.

Figure 5. Template for patch application on subject forehead. Red boxes were
utilized during first session. Green boxes were used during second session to
minimize potential confounding and carryover effect of drugs.
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Our research subjects were monitored with fixed gain reflective PPG (ADI

probe: Novametrix Medical Systems Inc) interfaced via bridge amplifer to data
acquisition system, LabChart (ADInstruments, Boulder CO), at the time of application
and every 8 minutes afterwards for 40 minutes with sampling frequency of 200 Hz (See
Figure 6). Continuous monitoring was not performed in order to minimize any
confounding risk of probe heating on vasodilation.

Figure 6. PPG sample of a research subject undergoing the experimental protocol for
nicotine, EMLA and control. Upper three panels show the raw PPG signal. Lower three
panels show the filtered AC signal. From left to right, columns designate pre-testing
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baseline, baseline at 0 minutes at initial patch application, 8 minutes afterward, and 16
minutes afterward.

Previous studies from our laboratory have shown that a voltage to volume
conversion based upon pulsatile volume at rest allows volume monitoring using a PPG
when resting stroke volume is known (measured or estimated). That is to say, one is
able to distinguish between arterial and venous components of the PPG signal under
certain assumptions. Our previous work has shown that PPG monitoring at a site
relatively devoid of vasoconstrictive activity (e.g., forehead) reveals relative degrees of
pulsatile and nonpulsatile blood volume similar to the 3000/125 (~24/1) relationship
between circulating venous volume and stroke volume. Thus, all voltage changes can be
expressed as “AC multiples at rest,” or “AC equivalents,” i.e., in multiples of the
change in voltage associated with the pulsatile delivery of the stroke volume to the
given site under resting conditions [12]. The AC multiple at rest is associated with an
AC voltage at rest; this voltage then becomes the calibrating voltage that one can then
use to make sense of changes in AC and DC in terms of multiples of “stroke volume.”
This estimation is used because AC is independent of background and normalizing to
the AC found at rest eliminates impact of attenuation. Thus, when a baseline stroke
volume is available (e.g., 125 ml as measured by echo or estimated from population
average), change in volume (in ml) can be calculated from the PPG based upon the
following conversion:
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Stroke volume at rest = 125 ml = 1 [AC multiples at rest] ~ AC calibrating
voltage = [AC voltage at rest].

Change in volume (in ml) can be calculated in one of two ways.
= ‘Given reading in [AC multiples at rest]’ x ‘125 ml/1 [AC multiples at rest]’
or
= ‘Given readings in volts’ x ‘125 ml/[AC voltage at rest]’

ANALYSIS
All PPG waveforms were extracted by ADInstruments LabChart. A linear mixed
model was used to compare the patch effects on maximum change in AC, maximum
change in DC, and maximum change in ΔAC/ΔDC. This model accounts for the
treatment group, day of study, repeated subjects, the sequence of treatment, and the
variance attributable to an individual’s multiple measurements with an unstructured
covariance matrix. Sequence of treatment refers to which order the subject received
sildenafil and placebo on day 1 and day 2 of the study. Subjects were treated as random
effects in the model. A p-value <0.05 was considered significant. Analyses was
conducted on the assumption that controls can be pooled together.
From the raw data sets, the median values of the first 20 data points at each time
segment for each patch on each day of study were calculated. Median was chosen as the
statistic to use due to the fact that the sample mean can often be unduly influenced by
outliers. The 0-minute time segment AC value for each patch on each day of study were
used as denominators to calculate AC equivalents for all corresponding median AC and
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DC values. The ΔAC and ΔDC values were calculated as changes in raw and AC
equivalents from the 0-time segment values for each patch.
Maximum ΔAC and ΔDC values for each patch on each day of study were
determined from the 0 to 40-minute data for patches NTG, nicotine, Exelon and its
associated controls. Magnitude comparisons of changes in AC and DC in terms of
absolute AC equivalents between patches were not done because drug patches weren’t
dose equivalent. Thus, max changes in the ratio between AC and DC were also obtained
in similar fashion for each patch since the comparison of a ratio nullifies the dose
effects of each patch, i.e., the apparent dose of drug that induced a certain change in AC
should be of the same factor as that which induces the change in DC as well.
For patches EMLA and its associated control, maximum ΔAC and ΔDC values
for each patch on each day of study were assumed to be at time segment 0, which was
compared to a baseline taken 6 hours prior to application.

RESULTS
As shown in table 1, within the placebo session, the maximum ΔAC (in AC
equivalents) was 1.211 units higher in Exelon compared to its paired control
(p=0.0223). The maximum ΔDC (in AC equivalents) was -5.099 compared to its paired
control, but this was not statistically significant. The maximum Δ(ΔAC/ΔDC) is 0.174
higher in Exelon compared to its paired control; this is a marginally significant
difference (p=0.0554).
The maximum ΔAC (in AC equivalents) was 1.387 units higher in NTG
compared to its paired control (p=0.0002). The maximum ΔDC (in AC equivalents)
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was 37.479 compared to its paired control (p=0.0037). The maximum Δ(ΔAC/ΔDC) is
0.001 higher in NTG compared to its paired control; this was not statistically
significant.
The maximum ΔAC (in AC equivalents) was 2.352 units higher in EMLA
compared to its paired control (p<0.0001). The maximum ΔDC (in AC equivalents)
and the maximum Δ(ΔAC/ΔDC) was not significantly different compared to its paired
control.
The maximum ΔAC (in AC equivalents) was 2.581 units higher in nicotine
compared to its paired control (p=0.0002). The maximum ΔDC (in AC equivalents)
and the maximum Δ(ΔAC/ΔDC) was not significantly different compared to its paired
control.
Table 1. Comparison of drug patch to control with regard to max ΔAC, max ΔDC, max
Δ(ΔAC/ ΔDC) within the placebo session (in terms of AC equivalents)
Max ΔAC
Max ΔDC (AC eq.)
(AC eq.)
Estimate
Patch
[95% CI] p-value Estimate [95% CI]
1.211
0.0223
-5.099
[ 0.217,
*
[-29.378, 19.180]
Exelon
2.206]
1.387
0.0002
37.479
[ 0.862,
*
[ 15.648, 59.309]
NTG
1.911]
2.352
0.0002
10.757
[ 1.466,
*
[-28.937, 50.451]
EMLA
3.238]
2.581
<.0001
34.270
[ 2.098,
*
[ -5.117, 73.658]
Nicotine
3.063]
*Denotes a p-value that is statistically significant

p-value
0.6460

Max
Δ(ΔAC/ΔDC)
Estimate [95%
CI]
0.174
[ -0.005, 0.353]

p-value
0.0554

0.0037
*

0.001
[ -0.223, 0.225]

0.9926

0.555

0.031
[ -0.799, 0.862]

0.9335

0.0806

-0.224
[ -0.666, 0.217]

0.2799
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When comparing the effects of different drugs, the max change in ΔAC/ΔDC ratio was
used as a way to control for differing dosing equivalents of drug patches. As shown in
Table 2, comparisons between all possible combinations of drug patches were
calculated. Some values are repeated albeit in the opposite direction (e.g., -0.262 vs
0.262 with regard to EMLA vs Exelon) depending on which drug patch was set as the
reference of comparison during analysis. As can be seen, there are no significant
differences between drug patches within the placebo session with regard to max
Δ(ΔAC/ΔDC).
Table 2. Comparison of max change of ΔAC/ΔDC between drug patches within the

placebo session
Max Δ(ΔAC/ΔDC)
Patch Comparison
vs Exelon
EMLA
NTG
Nicotine

Estimate [95% CI]

p-value

-0.262 [ -0.719, 0.195]
-0.075 [ -0.208, 0.058]
-0.016 [ -0.193, 0.161]

0.2275
0.2348
0.8414

vs Nicotine
EMLA
Exelon
NTG

-0.246 [ -0.605, 0.113]
0.016 [ -0.161, 0.193]
-0.059 [ -0.152, 0.034]

0.1558
0.8414
0.1873

vs NTG
EMLA
Exelon
Nicotine

-0.187 [ -0.563, 0.189]
0.075 [ -0.058, 0.208]
0.059 [ -0.034, 0.152]

0.2902
0.2348
0.1873

vs EMLA
Exelon
NTG
Nicotine

0.262 [ -0.195, 0.719]
0.187 [ -0.189, 0.563]
0.246 [ -0.113, 0.605]

0.2275
0.2902
0.1558
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Table 3 compares EMLA at its max effect, which is specifically found at time 0 (PPG
monitoring directly after removal of EMLA status post pretreatment of 6-hour
duration), against all other drug patches at 8 minutes, 16 minutes and 24 minutes during
the placebo session. Again, because of dose equivalency considerations, ΔAC/ΔDC
ratios were utilized. EMLA was used as the reference group.
Table 3A. Comparison of ΔAC/ΔDC ratios at EMLA time 0 and time 8 minutes for
other patches during the placebo session.
ΔAC/ΔDC within Placebo
Patch
Estimate [95% CI]
p-value
-.07875
0.0082*
Exelon
[-.13149,-.02600]
-.03114
0.1334
NTG
[-.07383,.011554]
.020799
0.6756
Nicotine
[-.08800,.129594]
-.07716
0.0383*
Control
[-.14914,-.00518]
*Denotes a p-value that is statistically significant
As shown in Table 3A, during the placebo session, the ΔAC/ΔDC ratio was -0.079 units
lower in Exelon at 8 minutes compared to EMLA at 0 minutes (p=0.008). The ratio of
the control at 8 minutes was 0.08 units lower compared to the ratio of EMLA at 0
minutes (p=0.04).
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Table 3B. Comparison of ΔAC/ΔDC ratios at EMLA time 0 and time 16 minutes for
other patches during the placebo session.

Patch
Exelon
NTG
Nicotine
Control

ΔAC/ΔDC within Placebo
Estimate [95% CI]
.033609
[-.08899,.156211]
-.03177
[-.07981,.016262]
-.03484
[-.10243,.032744]
-.05746
[-.11836,.003445]

p-value
0.5505
0.1688
0.2735
0.0616

As shown in Table 3B, there were no significant differences between the EMLA
ΔAC/ΔDC ratio at 0 minutes and the ΔAC/ΔDC ratio for other patches at 16 minutes
during the placebo session.
Table 3C. Comparison of ΔAC/ΔDC ratios at EMLA time 0 and time 24 minutes for
other patches during the placebo session.

Patch
Exel
NTG
Nico
CtrlN

ΔAC/ΔDC within Placebo
Estimate [95% CI]
-.03907
[-.10351,.025375]
-.03257
[-.07733,.012184]
-.02888
[-.08427,.026507]
-.03895
[-.25341,.175500]

p-value
0.2035
0.1341
0.2684
0.6908

As shown in Table 3C, there were no significant differences between the EMLA
ΔAC/ΔDC ratio at 0 minutes and the ΔAC/ΔDC ratio for other patches at 24 minutes
during the placebo session. Across these comparisons, EMLA tends to have the highest
ΔAC/ΔDC ratio, but as mentioned, most of these differences are not significant.

	
  

25	
  

DISCUSSION
The PPG is a powerful tool replete with information that has yet to be fully
understood. Given its ability to observe changes in blood circulation in local cutaneous
tissue, it is a great tool to understand the mechanisms and effects of different drugs at
the level of the microvasculature. In our study, we aim to understand the differences
between four locally targeted vasodilators including NTG, nicotine, rivastigmine, and
EMLA with regard to changes in venous and arterial microcirculation. This study
attempts to lay the foundational groundwork for future phases and studies in which
additive drug combinations are “layered” systemically on top of locally targeted drugs.
This is the concept of the “dual platform” drug model to assess pharmacological
interactions in a localized and controlled manner that minimizes systemic risk.
As seen in our results, all four drugs resulted in significant increases in the AC
component of the PPG as compared to control. For example, in terms of AC equivalents
or stroke volume equivalents, nicotine showcased the largest AC increase with 2.581
AC equivalents versus rivastigmine with an increase of 1.211 AC equivalents. If we
take resting stroke volume to be 125ml, a 2.581 AC equivalent increase is estimated to
be an increase in 322.625 ml versus 151.375 ml with regard to rivastigmine. Though
these increases seem to be vastly different, we must remember that our patches are not
dosed equivalently. A direct comparison of patches that take into consideration dosing
differences using changes in the ratio of AC and DC does not show the patches to be
statistically significantly different. This again extends not just to nicotine versus EMLA,
but to all possible drug comparison combinations in our study. While this conversion is
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not relevant to local changes in the microvasculature, it may prove valuable in the
context of challenges and changes in systemic volume.
Interestingly, NTG was the only drug that resulted in significantly increased
changes in DC along with significantly increased changes in AC. It is known that
nitrates predominantly cause the dilation of peripheral veins, and in higher doses, cause
the dilation of peripheral arteries [13]. As an exogenous organic nitrate, it likely
releases nitric oxide (NO) near vascular smooth muscle cells both before and after the
pre-capillary sphincter, acting in conjunction on both the arterial and venous side within
the local microvasculature.
Parasympathetic ganglion and post-ganglionic parasympathetic fibers have been
considered as potential mediators of vasodilation in the peripheral microvasculature
[14]. Since the arteriole-capillary-venule microvasculature is not a homogeneous
system, differences in the extent of autonomic innervation, where endogenous NO is
produced and where NO can act may influence the extent of vasodilation measured. In
contrast to NTG, acetylcholine (ACh) and nicotine administered peripherally via
micropatches are likely activators of postganglionic parasympathetic fibers, which
induce the release of ACh [15]. Nitric oxide synthase is constitutively present in
endothelial cells; ACh induces endothelium-dependent vasodilation and stimulates
nitric oxide synthase to produce endogenous NO, producing vasodilation in areas with
vascular smooth muscle tissue [16]. Thus, a transdermal acetylcholinesterase inhibitor
like rivastigmine (or nicotine directly) will be able to prolong the effects of ACh within
the parasympathetic ganglion and induce vasodilation through endothelium-dependent
processes. Our study seems to show that these postganglionic parasympathetic fibers
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may be more predominantly concentrated at (rather than beyond) the pre-capillary
sphincter, thus resulting in more of an arterial vasodilatory effect.
On the other hand, EMLA (an eutectic mix of local anesthetics), which blocks
all sodium channels in nerves, would block transmission of all electrical impulses in the
periphery [17]. Since blood vessels are held under a certain level of constant
vasoconstriction through sympathetic activity, the release of this constriction via EMLA
produces vasodilation where sympathetic activity was seen previously. Though we are
not able to discern or isolate the potential for off-target effects that EMLA may produce
within the local area, our study seems to indicate that the primary measurable
vasodilatory effect was isolated to the arterial microcirculatory system before the precapillary sphincter.
When we use EMLA as a reference for comparison, interesting temporal
relationships are observed. Because of the time it takes for EMLA to permeate through
the upper epidermal layer, we pretreated a designated site 6 hours before our main
experimental protocol. This 6-hour timeframe was determined through repeated
experimentation as the minimum amount of time needed for measurable effects to be
seen via PPG. Thus, at “time 0” when the other drug patches were placed and the
EMLA cream removed before monitoring (due to the cream being opaque in nature),
PPG measurements of the EMLA site should demonstrate maximal vasodilation, an
effect confirmed by our experimental protocol. As expected, the vasodilatory effects of
a “control patch” was significantly lower than that of EMLA at its peak effect as
measured by changes in the AC to DC ratio. Of note, the vasodilatory effects of
rivastigmine at 8 minutes were also significantly lower than that of EMLA at time 0;
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this difference disappeared at 16 minutes and beyond. It is also important to note that
this phenomenon was not observed in any other drug patch, i.e., the effects of other
drug patches were not significantly different from that of EMLA at 8 minutes or
beyond. Rivastigmine is unique among the drugs that we tested as the sole
acetylcholinesterase inhibitor [18]; it prolongs the effect of of ACh within the
parasympathetic ganglion by preventing its breakdown and thereby induce vasodilation
through endothelium-dependent processes. We hypothesize that this particular temporal
“delay of effect” with regard to rivastigmine at 8 minutes represents a sort of
“enzymatic lag” that may reflect the time needed for acetylcholine to “build-up” in the
synaptic cleft via the inhibition of its breakdown as opposed to an immediate
introduction of additional agonist via the nicotine or NTG patch. Further repeated
testing in the future will be conducted to confirm this hypothesis.
A main limitation of this study revolves around the use of the ADI probe, a
research PPG device that unfortunately causes local tissue warming and thus,
potentially introduces a source of external vasodilation unrelated to the drug patches
themselves. We tried to remedy this issue by using the probe only in one minute
intervals (every 8 minutes) to minimize probe heating; still, it is uncertain how much
variability this may have introduced into the study. Development of a probe that can
provide a DC signal without relying on a research probe that causes local tissue
warming would be ideal.
As stated, this paper represents the first phase of study in which we lay the
foundation for understanding the complex physiology of the microvasculature. Future
analysis will explore this environment with different and/or additive drug combinations
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to further elucidate the physiological interaction between several different drug
combinations in a safe and reproducible manner, particularly in conjunction with
sildenafil taken systemically. Evidence indicates that Alzheimer’s disease may be
derived from a vascular pathology characterized by cerebral hypoperfusion and that
pharmacotherapy that improves cerebral perfusion often lowers neurodegenerative
symptoms [19]. If it is possible to find a drug combination that can maximally induce
vasodilation within the microvasculature while minimizing systemic hypotensive risk,
clinical applications may exist for Alzheimer’s and other more well known
cardiovascular diseases.

CONCLUSION
In summary, the PPG may be used as a non-invasive monitor of arterial and venous
microcirculation. We aimed to better elucidate the effects of various transdermal
vasodilators on the forehead microvasculature and understand the underlying
mechanisms at work for each drug. Such a study lays the groundwork for future
experiments exploring potential drug interactions in a safe and reproducible manner
devoid of systemic adverse effects.
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